Tag: source

Strasbourg, France and Charleroi, Belgium, June 11^th  2025 – Elkedonia SAS, a company pioneering a novel neuroplastogen approach to develop therapeutic agents to treat depression and other neuropsychiatric condition, announced today that it has closed an oversubscribed EUR 11.25 million Seed funding round. The round was co-led by Kurma Partners, WE Life Sciences and the French Tech Seed fund managed on behalf of the French government by Bpifrance as part of France 2030, with participation from Argobio, Angelini Ventures, CARMA Fund, Capital Grand Est and Sambrinvest. Elkedonia is bringing together stakeholders from across the European ecosystem, with headquarters in Strasbourg, France and an affiliate in Charleroi, Belgium.

Investment supports the development of first-in-class, non-addictive, non-hallucinogenic molecules with a non-synaptic target, differentiated from existing drugs

LEADING EDGE MATERIALS ANNOUNCES UP TO C$4,000,000 NON-BROKERED PRIVATE PLACEMENT

Strasbourg, France, et Charleroi, Belgique, 11 juin 2025 - Elkedonia SAS, société pionnière dans le développement de neuroplastogènes thérapeutiques destinés à traiter la dépression et d'autres maladies neuropsychiatriques, a annoncé aujourd'hui un tour de financement d’amorçage de 11,25 millions d'euros. Ce tour de table a été co-dirigé par Kurma Partners, WE Life Sciences et le fonds French Tech Seed géré pour le compte du gouvernement français par Bpifrance dans le cadre de France 2030, avec la participation d'Argobio, Angelini Ventures, CARMA Fund, Capital Grand Est et Sambrinvest. Elkedonia rassemble plusieurs acteurs de l'écosystème européen, avec un siège à Strasbourg, en France, et une filiale à Charleroi, en Belgique.

On 10 June, 2025 AB Artea bankas (the Bank) has completed its own share (ISIN code LT0000102253) buy-back programme on the regulated market, which was carried out from 5 May, 2025. During this period, the Bank acquired 2,540,000 treasury shares, i.e. 96 % of the maximum number of shares within the limit set at the time of the programme's expiry, for a total amount of EUR 2,225,741.28, at an average price of EUR 0.876 per share.

London, UK, 11 June 2025 - Persica Pharmaceuticals Limited (Persica), a clinical stage biotechnology company developing a transformative treatment for chronic Low Back Pain (cLBP), today announces that it has been granted a patent by the European Patent Office for PP353, its clinical stage asset.

With rapid innovation and deep industry partnerships, Turntide empowers OEMs with flexible systems-level solutions for next-gen mobility.

Powered by 100% hydroelectric energy, the 12MW facility expands Crusoe Cloud’s data center footprint in Europe